Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
1. NPCE released one-year results from the NAUTILUS study for RNS System. 2. 12-week safety endpoint met, showing low serious adverse event rates. 3. Overall primary effectiveness endpoint was not statistically significant. 4. Subgroup data revealed significant effectiveness in patients with fewer seizures. 5. Sales grew 24% to $22.5 million in Q1 2025; sales guidance raised.